129 related articles for article (PubMed ID: 29103081)
1. A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events.
Goldsmith P; Affinito J; McCue M; Tsai M; Roepcke S; Xie J; Gertsik L; Macek TA
Drugs R D; 2017 Dec; 17(4):631-643. PubMed ID: 29103081
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor.
Tsai M; Chrones L; Xie J; Gevorkyan H; Macek TA
Psychopharmacology (Berl); 2016 Oct; 233(21-22):3787-3795. PubMed ID: 27572830
[TBL] [Abstract][Full Text] [Related]
3. Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor.
Macek TA; Suzuki K; Asin K; Kimura H
Int J Neuropsychopharmacol; 2020 Nov; 23(8):524-532. PubMed ID: 32598478
[TBL] [Abstract][Full Text] [Related]
4. A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia.
Macek TA; McCue M; Dong X; Hanson E; Goldsmith P; Affinito J; Mahableshwarkar AR
Schizophr Res; 2019 Feb; 204():289-294. PubMed ID: 30190165
[TBL] [Abstract][Full Text] [Related]
5. A human [(11)C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor.
Takano A; Stenkrona P; Stepanov V; Amini N; Martinsson S; Tsai M; Goldsmith P; Xie J; Wu J; Uz T; Halldin C; Macek TA
Neuroimage; 2016 Nov; 141():10-17. PubMed ID: 27423256
[TBL] [Abstract][Full Text] [Related]
6. TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms.
Suzuki K; Harada A; Suzuki H; Miyamoto M; Kimura H
Neuropsychopharmacology; 2016 Aug; 41(9):2252-62. PubMed ID: 26849714
[TBL] [Abstract][Full Text] [Related]
7. A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects.
Yurgelun-Todd DA; Renshaw PF; Goldsmith P; Uz T; Macek TA
Psychopharmacology (Berl); 2020 Feb; 237(2):317-328. PubMed ID: 31773211
[TBL] [Abstract][Full Text] [Related]
8. Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor.
Harada A; Suzuki K; Kamiguchi N; Miyamoto M; Tohyama K; Nakashima K; Taniguchi T; Kimura H
PLoS One; 2015; 10(3):e0122197. PubMed ID: 25815469
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 10A Inhibitor Monotherapy Is Not an Effective Treatment of Acute Schizophrenia.
Walling DP; Banerjee A; Dawra V; Boyer S; Schmidt CJ; DeMartinis N
J Clin Psychopharmacol; 2019; 39(6):575-582. PubMed ID: 31688451
[TBL] [Abstract][Full Text] [Related]
10. In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents.
Suzuki K; Harada A; Shiraishi E; Kimura H
J Pharmacol Exp Ther; 2015 Mar; 352(3):471-9. PubMed ID: 25525190
[TBL] [Abstract][Full Text] [Related]
11. TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia.
Suzuki K; Kimura H
CNS Neurosci Ther; 2018 Jul; 24(7):604-614. PubMed ID: 29318783
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
13. Brain PET measurement of PDE10A occupancy by TAK-063, a new PDE10A inhibitor, using [11 C]T-773 in nonhuman primates.
Takano A; Stepanov V; Nakao R; Amini N; Gulyás B; Kimura H; Halldin C
Synapse; 2016 Jun; 70(6):253-63. PubMed ID: 26878349
[TBL] [Abstract][Full Text] [Related]
14. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.
Harada A; Suzuki K; Kimura H
J Pharmacol Exp Ther; 2017 Jan; 360(1):75-83. PubMed ID: 27811172
[TBL] [Abstract][Full Text] [Related]
15. The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models.
Shiraishi E; Suzuki K; Harada A; Suzuki N; Kimura H
J Pharmacol Exp Ther; 2016 Mar; 356(3):587-95. PubMed ID: 26675680
[TBL] [Abstract][Full Text] [Related]
16. The phosphodiesterase 10A selective inhibitor, TAK-063, induces c-Fos expression in both direct and indirect pathway medium spiny neurons and sub-regions of the medial prefrontal cortex in rats.
Nakatani A; Nakamura S; Kimura H
Neurosci Res; 2017 Dec; 125():29-36. PubMed ID: 28687229
[TBL] [Abstract][Full Text] [Related]
17. In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects.
Delnomdedieu M; Forsberg A; Ogden A; Fazio P; Yu CR; Stenkrona P; Duvvuri S; David W; Al-Tawil N; Vitolo OV; Amini N; Nag S; Halldin C; Varrone A
Neuropharmacology; 2017 May; 117():171-181. PubMed ID: 28122201
[TBL] [Abstract][Full Text] [Related]
18. First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males.
Moschetti V; Boland K; Feifel U; Hoch A; Zimdahl-Gelling H; Sand M
Br J Clin Pharmacol; 2016 Nov; 82(5):1315-1324. PubMed ID: 27378314
[TBL] [Abstract][Full Text] [Related]
19. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
20. The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers.
Moschetti V; Kim M; Sand M; Wunderlich G; Andersen G; Feifel U; Jang IJ; Timmer W; Rosenbrock H; Boland K
Eur Neuropsychopharmacol; 2018 May; 28(5):643-655. PubMed ID: 29567399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
